Cognitive Disorders Anita Amelia Thompson Heisterman
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Assessment of Confabulation in Patients RENSON Publishedonline11sepetember2015 GREEN
King’s Research Portal DOI: 10.1080/13854046.2015.1084377 Document Version Peer reviewed version Link to publication record in King's Research Portal Citation for published version (APA): Renson, Y. C. M., Oosterman, J. M., van Damme, J. E., Griekspoor, S. I. A., Wester, A. J., Kopelman, M. D., & Kessels, R. P. C. (2015). Assessment of Confabulation in Patients with Alcohol-Related Cognitive Disorders: The Nijmegen–Venray Confabulation List (NVCL-20). The Clinical Neuropsychologist, 29, 804-823. https://doi.org/10.1080/13854046.2015.1084377 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. -
What Is It Like to Be Confabulating?
What is it like to be Confabulating? Sahba Besharati, Aikaterini Fotopoulou and Michael D. Kopelman Kings College London, Institute of Psychiatry, London UK Different kinds of confabulations may arise in neurological and psychiatric disorders. This chapter first offers conceptual distinctions between spontaneous and momentary (“provoked”) confabulations, as well as between these types of confabulation and other kinds of false memories. The chapter then reviews current explanatory theories, emphasizing that both neurocognitive and motivational factors account for the content of confabulations. We place particular emphasis on a general model of confabulation that considers cognitive dysfunctions in memory and executive functioning in parallel with social and emotional factors. It is argued that all these dimensions need to be taken into account for a phenomenologically rich description of confabulation. The role of the motivated content of confabulation and the subjective experience of the patient are particularly relevant in effective management and rehabilitation strategies. Finally, we discuss a case example in order to illustrate how seemingly meaningless false memories are actually meaningful if placed in the context of the patient’s own perspective and autobiographical memory. Key words: Confabulation; False memory; Motivation; Self; Rehabilitation. 1 Memory is often subject to errors of omission and commission such that recollection includes instances of forgetting, or distorting past experience. The study of pathological forms of exaggerated memory distortion has provided useful insights into the mechanisms of normal reconstructive remembering (Johnson, 1991; Kopelman, 1999; Schacter, Norman & Kotstall, 1998). An extreme form of pathological memory distortion is confabulation. Different variants of confabulation are found to arise in neurological and psychiatric disorders. -
Behavorial Health Department – Primary Care Center and Fireweed Treatment Guidelines for Cognitive Disorders
BEHAVORIAL HEALTH DEPARTMENT – PRIMARY CARE CENTER AND FIREWEED TREATMENT GUIDELINES FOR COGNITIVE DISORDERS EXECUTIVE SUMMARY .................................................................................................... 2 INTRODUCTION AND STATEMENT OF INTENT .................................................................................2 DEFINITION OF DISORDER......................................................................................................2 GENERAL GOALS OF TREATMENT ..............................................................................................3 SUMMARY OF 1ST, 2ND AND 3RD LINE TREATMENT ............................................................................3 CLINICAL AND DEMOGRAPHIC ISSUES THAT INFLUENCE TREATMENT PLANNING..........................................3 FLOW DIAGRAM ............................................................................................................. 4 ASSESSMENT.................................................................................................................. 5 PSYCHIATRIC ASSESSMENT ....................................................................................................5 PSYCHOLOGICAL TESTING ......................................................................................................5 SCREENING/SCALES ............................................................................................................5 MODALITIES & TREATMENT MODELS............................................................................. -
Functional–Anatomic Correlates of Control Processes in Memory
The Journal of Neuroscience, May 15, 2003 • 23(10):3999–4004 • 3999 Functional–Anatomic Correlates of Control Processes in Memory Randy L. Buckner Department of Psychology, Howard Hughes Medical Institute at Washington University, St. Louis, Missouri 63130 Introduction when memory retrieval requires flexible use of control processes A central role for control processes in long-term memory is ap- (Milner et al., 1985; Schacter, 1987; Shimmamura et al., 1991). In parent when one considers that there is far more information many cases, patients will fail to recall, or sometimes even recog- available in memory than can be accessed at any single moment nize, information (for review, see Wheeler et al., 1995) or inap- (Tulving and Pearlstone, 1966; Koriat, 2000). Much as selective propriately estimate the source or timing, or both, of a past epi- attention operates to focus processing on objects in the environ- sode (for review, see Schacter, 1987). In rare cases, a patient may ment, related control processes are required to constrain and make up episodes from the past while believing they really hap- select from information stored in memory. pened, a phenomenon called “confabulation” (Moscovitch, Neuroimaging studies have expanded our understanding of 1989; Burgess and Shallice, 1996). Unlike purer forms of amnesia, control processes in long-term memory in three important ways. which result from medial temporal and diencephalic lesions First, networks of regions, prominently including specific regions (Scoville and Milner, 1957; Squire, 1992; Cohen and Eichen- in prefrontal cortex, contribute to control processes during baum, 1993), the deficits after frontal damage align more to im- memory retrieval. -
Antipsychotic Medication Reduction
So tonight we'll be discussing antipsychotic medication reduction. I'm happy to share some of my experiences with this challenging initiative and in nursing homes. I have no financial affiliations to disclose. And for our objectives and our agenda today, we're going to assess and evaluate appropriate antipsychotic medication use in nursing home residents, and apply strategies toward behavior management and antipsychotic medication reduction. The first part of the program we'll look at current trends and rates of antipsychotic medication use. We'll discuss the CMS initiative and latest policy issues. And then we'll look at a couple case studies. So first off, this first graph goes over the national progress in reducing the inappropriate use of antipsychotic medications in nursing homes. The taller red bar gives us the 2011 baseline number of 23.9%. That's a dotted red line indicates the start of the 2012 CMS initiative. That's the National Partnership to Improve Dementia Care in Nursing Homes. The latest information all the way down at the end is from the third quarter of 2018, which shows that nationally we have a 14.6% use rate. Overall, this looks like a reduction of nearly 40% since the initiative began. Overall though, I think this is great progress. Why should we be concerned with antipsychotic medications at all in this population? I have to say, that when I first exited my training from psychiatry and geriatric psychiatry, the black box warning had not yet come out. And it hit me that most of all the training that I learned was getting reversed when I entered the care setting. -
Metacognition in Functional Cognitive Disorder
medRxiv preprint doi: https://doi.org/10.1101/2021.06.24.21259245; this version posted June 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Title Page Title: Metacognition in Functional Cognitive Disorder Short Running Title: Functional Cognitive Disorder Authors: Rohan Bhome,1,* Andrew McWilliams,2,3,4,* Gary Price5, Norman A Poole6, Robert J Howard7, Stephen M Fleming3,8,9, Jonathan D Huntley7 *These authors contributed equally to this work 1. Dementia Research Centre, University College London, 8-11 Queen Square, London, UK 2. Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London UK. 3. Wellcome Centre for Human Neuroimaging, University College London, UK. 4. UCL Institute of Child Health, Great Ormond Street, London, UK. 5. National Hospital for Neurology and Neurosurgery, London, UK 6. South West London and St George's Mental Health NHS Trust, London, UK 7. Division of Psychiatry, University College London, London, UK 8. Max Planck University College London Centre for Computational Psychiatry and Ageing Research, London, UK 9. Department of Experimental Psychology, University College London, London, UK Correspondence to: Dr Rohan Bhome, Dementia Research Centre, University College London, 8-11 Queen Square, WC1N 3AR, [email protected] Word count: 4176 words 4 tables, 3 figures NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. -
Psychotropic Medication Concerns When Treating Individuals with Developmental Disabilities
Tuesday, 2:30 – 4:00, C2 Psychotropic Medication Concerns when Treating Individuals with Developmental Disabilities Richard Berchou 248-613-6716 [email protected] Objective: Identify effective methods for the practical application of concepts related to improving the delivery of services for persons with developmental disabilities Notes: Medication Assistance On-Line Resources OBTAINING MEDICATION: • Needy Meds o Needymeds.com • Partnership for Prescriptions Assistance o Pparx.org • Patient Assistance Program Center o Rxassist.org • Insurance coverage & Prior authorization forms for most drug plans o Covermymeds.com REMINDERS TO TAKE MEDICATION: • Medication reminder by Email, Phone call, or Text message o Sugaredspoon.com ANSWER MOST QUESTIONS ABOUT MEDICATIONS: • Univ. of Michigan/West Virginia Schools of Pharmacy o Justaskblue.com • Interactions between medications, over-the-counter (OTC) products and some foods; also has a pictorial Pill Identifier: May input an entire list of medications o Drugs.com OTHER TRUSTED SITES: • Patient friendly information about disease and diagnoses o Mayoclinic.com, familydoctor.org • Package inserts, boxed warnings, “Dear Doctor” letters (can sign up to receive e- mail alerts) o Dailymed.nlm.nih.gov • Communications about drug safety o www.Fda.gov/cder/drug/drugsafety/drugindex.htm • Purchasing medications on-line o Pharnacychecker.com Updated 2013 Psychotropic Medication for Persons with Developmental Disabilities April 23, 2013 Richard Berchou, Pharm. D. Assoc. Clinical Prof., Dept. Psychiatry & Behavioral -
Disordered Memory Awareness: Recollective Confabulation in Two Cases of Persistent Déj`A Vecu
Neuropsychologia 43 (2005) 1362–1378 Disordered memory awareness: recollective confabulation in two cases of persistent dej´ a` vecu Christopher J.A. Moulin a,b,∗, Martin A. Conway b, Rebecca G. Thompson a, Niamh James a, Roy W. Jones a a The Research Institute for the Care of the Elderly, St. Martin’s Hospital, UK b Institute of Psychological Sciences, University of Leeds, Leeds LS2 9JT, UK Received 7 April 2004; received in revised form 10 December 2004; accepted 16 December 2004 Available online 11 March 2005 Abstract We describe two cases of false recognition in patients with dementia and diffuse temporal lobe pathology who report their memory difficulty as being one of persistent dej´ a` vecu—the sensation that they have lived through the present moment before. On a number of recognition tasks, the patients were found to have high levels of false positives. They also made a large number of guess responses but otherwise appeared metacognitively intact. Informal reports suggested that the episodes of dej´ a` vecu were characterised by sensations similar to those present when the past is recollectively experienced in normal remembering. Two further experiments found that both patients had high levels of recollective experience for items they falsely recognized. Most strikingly, they were likely to recollectively experience incorrectly recognised low frequency words, suggesting that their false recognition was not driven by familiarity processes or vague sensations of having encountered events and stimuli before. Importantly, both patients made reasonable justifications for their false recognitions both in the experiments and in their everyday lives and these we term ‘recollective confabulation’. -
CHAPTER 6 Sleep and Stroke G.J
CHAPTER 6 Sleep and Stroke G.J. Meskill*, C. Guilleminault** *Comprehensive Sleep Medicine Associates, Houston, TX, USA **The Stanford Center for Sleep Sciences and Medicine, Redwood City, CA, USA OUTLINE Introduction 115 Stroke, Parasomnias, and Sleep- Related Movement Disorders 120 Sleep Apnea is a Risk Factor for Stroke 115 Diagnosis 120 Pathophysiology 116 Treatment 122 Stroke Increases the Risk of Sleep Apnea 118 Conclusions 123 Stroke and the Sleep–Wake Cycle 118 References 124 INTRODUCTION Stroke, defined as a focal neurological deficit of acute onset and vascular origin, is the sec- ond leading cause of death worldwide and is a major source of physical, psychological, and monetary hardship. There are more than 15 million cases worldwide annually, and 795,000 in the United States alone. In total, 137,000 stroke patients will die from stroke complications, and more than 50% will have physical and mental impairment.1 Factoring healthcare services, medications, and productivity loss, strokes cost the United States $34 billion annually.2 SLEEP APNEA IS A RISK FACTOR FOR STROKE Obstructive sleep apnea (OSA) is characterized by recurrent episodes of partial or complete interruption in breathing during sleep due to increased upper airway resistance. OSA has been identified as an independent risk factor for several cardiovascular and cerebrovascular Sleep and Neurologic Disease. http://dx.doi.org/10.1016/B978-0-12-804074-4.00006-6 Copyright © 2017 Elsevier Inc. All rights reserved. 115 116 6. SLEEP AND STROKE morbidities, including hypertension, ischemic heart disease, heart failure, atrial fibrillation, and hypertrophic cardiomyopathy.3–6 The incidence of OSA varies due to significant differ- ences in the sensitivity of testing sites, testing modalities (e.g., in-laboratory polysomnog- raphy vs. -
Alcohol and Brain Damage in Adults with Reference to High-Risk Groups
CR185 Alcohol and brain damage in adults With reference to high-risk groups © 2014 Royal College of Psychiatrists For full details of reports available and how to obtain them, contact the Book Sales Assistant at the Royal College of Psychiatrists, 21 Prescot Street, COLLEGE REPORT London E1 8BB (tel. 020 7235 2351; fax 020 3701 2761) or visit the College website at http://www.rcpsych.ac.uk/publications/collegereports.aspx Alcohol and brain damage in adults With reference to high-risk groups College report CR185 The Royal College of Psychiatrists, the Royal College of Physicians (London), the Royal College of General Practitioners and the Association of British Neurologists May 2014 Approved by the Policy Committee of the Royal College of Psychiatrists: September 2013 Due for review: 2018 © 2014 Royal College of Psychiatrists College Reports constitute College policy. They have been sanctioned by the College via the Policy Committee. For full details of reports available and how to obtain them, contact the Book Sales Assistant at the Royal College of Psychiatrists, 21 Prescot Street, London E1 8BB (tel. 020 7235 2351; fax 020 7245 1231) or visit the College website at http://www.rcpsych. ac.uk/publications/collegereports.aspx The Royal College of Psychiatrists is a charity registered in England and Wales (228636) and in Scotland (SC038369). | Contents List of abbreviations iv Working group v Executive summary and recommendations 1 Lay summary 6 Introduction 12 Clinical definition and diagnosis of alcohol-related brain damage and related -
The Three Amnesias
The Three Amnesias Russell M. Bauer, Ph.D. Department of Clinical and Health Psychology College of Public Health and Health Professions Evelyn F. and William L. McKnight Brain Institute University of Florida PO Box 100165 HSC Gainesville, FL 32610-0165 USA Bauer, R.M. (in press). The Three Amnesias. In J. Morgan and J.E. Ricker (Eds.), Textbook of Clinical Neuropsychology. Philadelphia: Taylor & Francis/Psychology Press. The Three Amnesias - 2 During the past five decades, our understanding of memory and its disorders has increased dramatically. In 1950, very little was known about the localization of brain lesions causing amnesia. Despite a few clues in earlier literature, it came as a complete surprise in the early 1950’s that bilateral medial temporal resection caused amnesia. The importance of the thalamus in memory was hardly suspected until the 1970’s and the basal forebrain was an area virtually unknown to clinicians before the 1980’s. An animal model of the amnesic syndrome was not developed until the 1970’s. The famous case of Henry M. (H.M.), published by Scoville and Milner (1957), marked the beginning of what has been called the “golden age of memory”. Since that time, experimental analyses of amnesic patients, coupled with meticulous clinical description, pathological analysis, and, more recently, structural and functional imaging, has led to a clearer understanding of the nature and characteristics of the human amnesic syndrome. The amnesic syndrome does not affect all kinds of memory, and, conversely, memory disordered patients without full-blown amnesia (e.g., patients with frontal lesions) may have impairment in those cognitive processes that normally support remembering. -
The ICD-10 Classification of Mental and Behavioural Disorders Diagnostic Criteria for Research
The ICD-10 Classification of Mental and Behavioural Disorders Diagnostic criteria for research World Health Organization Geneva The World Health Organization is a specialized agency of the United Nations with primary responsibility for international health matters and public health. Through this organization, which was created in 1948, the health professions of some 180 countries exchange their knowledge and experience with the aim of making possible the attainment by all citizens of the world by the year 2000 of a level of health that will permit them to lead a socially and economically productive life. By means of direct technical cooperation with its Member States, and by stimulating such cooperation among them, WHO promotes the development of comprehensive health services, the prevention and control of diseases, the improvement of environmental conditions, the development of human resources for health, the coordination and development of biomedical and health services research, and the planning and implementation of health programmes. These broad fields of endeavour encompass a wide variety of activities, such as developing systems of primary health care that reach the whole population of Member countries; promoting the health of mothers and children; combating malnutrition; controlling malaria and other communicable diseases including tuberculosis and leprosy; coordinating the global strategy for the prevention and control of AIDS; having achieved the eradication of smallpox, promoting mass immunization against a number of other